Portage Biotech Inc. (PRTG)
NASDAQ: PRTG · Real-Time Price · USD
4.550
-0.020 (-0.44%)
Nov 21, 2024, 1:24 PM EST - Market open

Company Description

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products.

Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors.

The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials.

Portage Biotech Inc. is based in Tortola, British Virgin Islands.

Portage Biotech Inc.
Portage Biotech logo
Country British Virgin Islands
Founded 1973
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Ian Walters

Contact Details

Address:
Clarence Thomas Building, P.O. Box 4649
Tortola, VG1110
British Virgin Islands
Phone 203 221 7378
Website portagebiotech.com

Stock Details

Ticker Symbol PRTG
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001095435
CUSIP Number G7185A128
ISIN Number VGG7185A1286
SIC Code 2834

Key Executives

Name Position
Dr. Ian B. Walters M.B.A., M.D. Chief Executive Officer and Chairman of Board
Dr. Robert A. Kramer Ph.D. Chief Scientific Officer
Brian Wiley Chief Business Officer
Eun-Jae Park CPA Chief Financial Officer
Adam Melero Controller

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Oct 4, 2024 424B3 Prospectus
Oct 4, 2024 6-K Report of foreign issuer
Oct 3, 2024 144 Filing
Sep 27, 2024 144 Filing
Sep 23, 2024 144 Filing
Sep 20, 2024 144 Filing
Sep 4, 2024 424B3 Prospectus
Sep 4, 2024 6-K Report of foreign issuer